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Question: The objective of the study was to prospectively evaluate an algorithmic approach to
the cause(s) of chronic dyspnea.
Materials/patients/methods: Prospective observational study. The study group consisted of
123 patients with a chief complaint of dyspnea of unknown cause present for >8 weeks. Dys-
pnea severity scores were documented at entry and after therapy. Patients underwent an algo-
rithmic approach to dyspnea. Therapy could be instituted at any time that data supported
a treatable diagnosis. Whenever possible, accuracy of diagnosis was confirmed with an
improvement in dyspnea after therapy. Tests required, spectrum and frequency of diagnoses,
and the values of individual tests were determined.
Results: Cause(s) was(were) diagnosed in 122/123 patients (99%); 97 patients had one diag-
nosis and 25 two diagnoses. Fifty-three percent of diagnoses were respiratory and 47% were
non-respiratory. Following therapy, dyspnea improved in 63% of patients.
Conclusions: The prospective algorithmic approach led to diagnoses in 99% of cases. A third of
patients were diagnosed with each tier of the algorithm, thus minimizing the need for invasive
testing. Specific diagnoses led to improvement in dyspnea in the majority of cases. Based on
the results of this study, the algorithm can be revised to further minimize unnecessary tests
without loss of diagnostic accuracy.
ª 2010 Elsevier Ltd. All rights reserved.6 342 2406; fax: þ1 856 541 3968.
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Dyspnea is a frequent, sometimes disabling complaint. It is
among the most common reasons for seeking medical
attention.1 Three prior studies have evaluated cohorts of
patients with a chief complaint of dyspnea to try and
diagnose the cause of dyspnea as well as the value of
specific tests.2e4 The results of these three studies showed
that the spectrum of diagnoses associated with dyspnea
was broad and included a number of cardiorespiratory as
well as non-cardiorespiratory disorders. They also demon-
strated the diagnostic value of pulmonary function tests
(PFTs) including methacholine bronchoprovocation chal-
lenge (BPC), chest roentgenogram (CXR) and cardiopulmo-
nary exercise testing (CPET).2e4 None of these studies,
however, employed a prospective algorithmic approach
that was applied in a systematic way to all patients.3
The goal of our study was to use an algorithmic approach
to the diagnostic evaluation of outpatients referred with
undiagnosed chronic dyspnea (i.e.>8 weeks). The algo-
rithm (i.e. the specific tests and sequence) was based upon
the prior studies2e4 as well as a review of the literature on
causes of dyspnea.5 It focused on the initial use of PFTs
including BPC to diagnose Chronic Obstructive Pulmonary
Disease (COPD) and asthma4 the CXR to detect parenchymal
lung and pleural disorders4 and blood tests to detect
anemia and heart failure. CPET followed when PFTs, CXR,
and blood tests failed to detect or suggest a cause.2e4 The
algorithm was designed with four primary goals in mind: 1)
to diagnose the cause(s) of dyspnea in every patient if
possible; 2) to sequence the testing to try and optimize
efficiency; 3) to use a beneficial response to therapy as
a way to help confirm diagnoses whenever possible; and 4)
to use the results of this study to streamline and revise the
diagnostic algorithm.
Patients and methods
Patients
The protocol was approved by the Institutional Review
Board of Cooper University Hospital. (Approval #05-039.)
Patients gave informed written consent.
Conflicts of interest: No author of this paper has any
financial or personal conflict of interest related to the
material presented herein. There was no study sponsor.
Patients referred to our university pulmonary practice
between September 2005 and December 2006 were eligible
for enrollment if they had a chief complaint of shortness of
breath present for at least eight weeks, it occurred at least
three days per week, interfered with normal activities, and
was of unknown cause.
Diagnostic protocol (Fig. 1)
Tier I
At the initial visit, each patient filled out a “Mahler Baseline
Dyspnea Index”6,7 and then underwent Tier I testing which
consisted of a history and physical examination (H&P), chest
roentgenogram (CXR), pulmonary function tests (PFTs), and
blood tests. PFTs included spirometry, lung volumes byplethysmography, diffusing capacity (DLCO), and a meth-
acholine bronchoprovocation challenge (BPC). If the forced
expiratory volume in 1 s (FEV1) was <70% of predicted, BPC
was not performed in order to avoid potentially dangerous
drops in lung function; instead, nebulized albuterol (2.5 mg)
wasadministered followedbyspirometry.Predictedvalues for
PFTs were based on published literature.8e10 BPC was per-
formed with the tidal volume nebulizer.11e13 PFTs provided
the primary basis for diagnosing asthma or COPD. Normal
spirometry with a positive MIC and response to therapy was
considered diagnostic of asthma. Baseline obstruction with
(near) normalization post bronchodilator (BD) or following
therapy was also considered diagnostic of asthma. Baseline
obstruction with failure to achieve normalization post BD as
well as following maximum therapy (plus a low DLCO) was
considered diagnostic of COPD. Emphysema without airflow
obstructionwasdiagnosed based on (near) normal spirometry,
a low DLCO and a Chest computerized tomographic (CT) scan
that showed significant emphysema.
Blood tests included blood count (CBC), basic chemis-
tries, thyroid stimulating hormone (TSH), and brain natri-
uretic peptide (BNP). (BNP or pro-BNP as mandated by
insurance).
At the initial visit, the physician predicted the cause of
dyspnea, first after the H&P and then after PFTs. These
predictions were later compared with final diagnoses.
The completion of Tier I represented a branch point. If
the H&P, blood tests, CXR, and PFTs strongly supported
a diagnosis (e.g. PFTs consistent with asthma), therapy was
prescribed. If dyspnea improved, the diagnosis was
considered confirmed. Alternatively, if Tier I results (þ/
therapy) did not confirm a diagnosis, Tier II was routinely
performed unless Tier I results suggested a diagnosis which
could be confirmed by a specific Tier III study. In those cases
Tier II (CPET) was bypassed.
Tier II- cardiopulmonary exercise testing (CPET)
Tier II (CPET) was performed if there was no diagnosis after
Tier I or an additional cause was suspected. If CPET
confirmed a diagnosis and no additional cause was sus-
pected, no further testing was done. If CPET did not
confirm a diagnosis, the results were used to select specific
Tier III studies. Exercise capacity was characterized as
normal or reduced based on maximal oxygen uptake (VO2
max),14 and any limitation was categorized as respiratory or
circulatory. It should be noted that echocardiography
(echo) was not included as part of Tier II. The CPET was
performed in the pulmonary laboratory by a pulmonologist.
Neither the equipment nor the expertise to perform and
interpret an echocardiogram was available.
Studies specific for that limitation were then ordered.
For example, if the CPET showed a circulatory limitation an
echocardiogram (echo) was typically obtained. Alterna-
tively, if the CPET suggested ischemia a nuclear cardiac
stress test or stress echo was ordered. (It may well be
desirable in the future to combine standard CPET with
echocardiography in centers designed for the diagnosis and
evaluation of patients with unexplained dyspnea.).
CPET results were part of the diagnostic criteria for
obesity and non-physiologic (i.e. psychogenic) dyspnea. A
reduced VO2/kg plus a normal VO2 max without cardiore-
spiratory dysfunction (and normal Tier I studies) was
Figure 1 Diagnostic protocol.
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normal CPET and Tier I was consistent with non-physiologic
(psychogenic) dyspnea. Two patients had a CPET that
showed a reduced VO2 max with a circulatory limitation
where the subsequent echos were normal, they reported
significant inactivity before onset of dyspnea and the
dyspnea resolved with exercise training. They were diag-
nosed with “deconditioning.” Two patients had normal Tier
I and II (CPET) testing, symptoms typical of post-nasal drip
syndrome (PNDS) with nasal congestion and dyspnea
resolved with standard treatment for PND. Two patients
with typical history (and previous diagnosis) of fibromyalgia
had normal Tier I and II (CPET) testing and improved with
treatment of their fibromyalgia.
The study design allowed any diagnostic evidence to be
followed promptly. As stated above, if Tier I strongly sug-
gested a diagnosis, CPET was bypassed, and a Tier III study
obtained (e.g., chest CT scan for suspected ILD on CXR).
Furthermore, whenever the data supported a diagnosis,
treatment could be instituted.
Tier III e focused organ-specific testing
Tier III tests tended to be single-organ-focused and
included invasive studies. Tests included Chest CT scanning,
bronchoscopy, echocardiogram (resting or exercise),
nuclear stress testing, and cardiac catheterization. Tier III
studies were ordered based on the composite results of Tier
I þ/ Tier II.
Response to therapy and Follow-up
Therapy was instituted whenever a diagnosis was consid-
ered probable and therapy was available. When the
treatment led to at least a moderate (based on Mahler
Transitional Dyspnea Index7) improvment in dyspnea, the
diagnosis was considered confirmed. The converse wastrue; if expected therapy did not lead to improvement, that
diagnosis was deemed incorrect and the work up resumed.
Statistical analysis
Mean differences between groups were tested for signifi-
cance using independent samples t-testing (two-sided,
p  0.05) with correction for equal variance assumptions
where indicated.Results
One hundred forty-eight consecutive patients met study
criteria. Six declined to participate and 19 failed to
complete the protocol. One hundred twenty-three patients
(48 men and 75 women) completed the protocol. Demo-
graphic data are presented in Table 1.Final diagnoses
A cause(s) of dyspnea was determined in 122/123 (99%)
patients. Ninety-seven had a single diagnosis and 25 two
diagnoses (total, 147 diagnoses). No diagnosis was deter-
mined for one patient. Almost half (47%) the diagnoses
were non-respiratory (Fig. 2). The spectrum and frequency
of diagnoses is shown in Table 2.
Tier evaluations and number of diagnostic tests
performed
A total of 524 diagnostic tests were performed on the 123
patients (mean, 4.3/patient). (CBC, BNP, TSH, and chem-
istries were counted as a “single blood test”. PFTs were
also counted as a “single test”.) After Tier 1, 162 additional
Table 1 Baseline characteristics of patients (n Z 123).
Age (years 60.2  15.1
Gender (n, %)
Male 48 (39.0)
Female 75 (61.0)
Body mass index (BMI) (kg/m2) 32  8.4
BMI > 30 (%) 57
BMI > 40 (%) 25
Mean Duration of dyspnea (months) 24.5  33.9
Dyspnea score 6  2.3
Table 2 Final diagnoses by category.
# patients %
1. Respiratory diagnoses 78 53
a. Airflow obstruction 55 37
i. Asthma 29 20
ii. Asthma/COPD 13 9
iii. COPD 13 9
b. Interstitial lung diseases 12 8
i. Usual interstitial
pneumonitis (UIP)
7 5
ii. Sarcoidosis 4 3
iii. Lymphangioleiomyomatosis 1 1
c. Other pulmonary disorders 11 7
i. Emphysema without airflow
obstruction
3 2
ii. Pulmonary hypertension 3 2
iii. Chronic pneumonia 1 1
iv. Lung cancer 1 1
v. Kyphoscoliosis with
ventilatory limitation
1 1
vi. Pleural disease 2 1
2. Cardiovascular and
circulatory diagnoses
23 16
a. Congestive heart failure/
cardiomyopathy (includes diastolic
dysfunction, systolic dysfunction,
and ischemic
heart disease)
9 6
b. Valvular heart disease 5 3
c. Other circulatory disorders 12 8
i. Anemia 5 3
ii. Inferior vena caval obstruction 1 1
iii. Chronotropic insufficiency 1 1
iv. Peripheral vascular disease 1 1
3. Non-cardiopulmonary diagnoses 46 31
a. Obesity 24 16
Diagnostic approach to chronic dyspnea 1017tests (67 CPET and 95 Tier III) were performed (mean 1.3
per patient). Fifty-three/123 patients underwent at least
one Tier III test.
Fig. 3 shows the flow of patients through the tiers. Forty-
five patients were diagnosed from Tier I. Sixty-seven
patients underwent CPET (Tier II), 60 who lacked a diag-
nosis after Tier I and 7 who had a diagnosis (asthma 5,
anemia 2), but for whom additional causes were suspected
(none were found). Thirty-eight patients were diagnosed
after CPET (particularly obesity and non-physiologic,
psychogenic dyspnea). Therefore, a diagnosis was made in
83/123 patients (67%) by the end of Tier II. Thirty-nine
patients were diagnosed from Tier III studies. One patient
had no diagnosis.
Although Tier I established a diagnosis in 45 patients,
suspicion that additional diagnoses might be present led to
Tier II evaluation in 7 and Tier III studies in 8; no additional
diagnoses were found. Similarly, 7 patients diagnosed by
Tier II went on to Tier III studies that were, again, of no
additional diagnostic value.
Accuracy of physician predictions
Physicians’ predictions following H&P were accurate 55% of
the time compared with final diagnoses. When PFT results
were added, accuracy increased to 72%.Figure 2 Diagnoses by category.
b. Non-physiologic (psychogenic) 15 10
c. Deconditioning 2 1
d. Fibromyalgia 2 1
e. Pregnancy 1 1
f. Post-nasal drip 2 1
Total diagnoses 147 100
YES
(N = 45)
NO
DIAGNOSIS
(N = 1) 
TIER III  
DIAGNOSTIC
(N = 39) 
TIER II 
DIAGNOSTIC 
(N = 38)  
TIER  I
DIAGNOSTIC
NO
(N = 78)
Figure 3 Flow of patients through tiers.
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asthma and COPD
Only 17/31 patients reporting a history of asthma had
asthma-related dyspnea (positive predictive value (PPV)
0.55). Only 13/29 patients reporting a history of COPD had
COPD-related dyspnea (PPV 0.45).
Diagnostic accuracy of smoking history for COPD
Of the 123 patients, 23were current smokers, 49 ex-smokers,
and 51 non-smokers. COPD (or isolated emphysema) was
diagnosed in 29 patients. All were either current or former
smokers. A smoking history had a Positive predictive value
(PPV) of 0.40 for COPD. A non-smoking history had a negative
predictive value of 1.0; (i.e., no non-smoker was diagnosed
with COPD). Therewas a significant difference inmean pack-
years between smokers with COPD (49.6  21.8, range
10e114), versus those without COPD (33.2  25.7, range
2e100). (pZ 0.002), but there was considerable overlap. No
patient with <10-pack-year history had COPD.
Diagnostic value of blood tests
One hundred and nineteen patients had hemoglobin
measured. Seventeen of the 119 hemoglobin levels (14%)
were low16 including 5 patients <10 gm/dl (9.6, 9.3, 9.1,
8.6, and 7.7). Anemia was determined to be a factor in all
5; dyspnea improved with increase in hemoglobin. In
patients with hemoglobin >10, other causes of dyspnea
were found.
One hundred and fifteen patients had a pro-BNP (nZ 72)
or BNP (n Z 43). In ninety-five patients, the values were
normal and in 20 they were elevated. Ninety-three/95
normal values were true negatives, and 2 were false
negatives (i.e., cardiomyopathy was the final diagnosis).
Nine/20 elevated values were true positives (diagnosis of
cardiomyopathy) and 11 were false positives. TSH and
chemistries were of no value in this study.
Diagnostic value of CXR
Sixty-nine/121 patients (57%) had a normal and 52 (43%) an
abnormal CXR. (Two patients did not have a CXR.) All 12
patients with interstitial lung disease (ILD) had CXRs
consistent with the diagnosis. Only 9/29 (31%) of patients
with COPD had CXR findings consistent with COPD (hyper-
inflation or bullae). Three patients with emphysema
without airflow obstruction all had normal CXRs. Ninety
percent (26/29) of asthmatics had normal CXRs. Three had
hyperinflation. Seven of 9 patients with cardiomyopathy
had cardiomegaly with interstitial changes, and 2 had
normal CXRs. The patients with lung cancer, fibrothorax
with pleural effusion, and scoliosis had the expected CXR
abnormalities. The patient with pneumonia had a normal
CXR. (Diagnosis made by CT scan and response to therapy).
In 13/14 patients with dyspnea due to isolated obesity, CXR
was normal. In summary, all patients with non-physiologic
(psychogenic) dyspnea or other non-cardiorespiratory
diagnoses (except 1 patient with obesity) had normal CXRs.
Most (90%) of asthmatics and the majority (69%) of patientswith COPD had normal CXRs. All patients with ILD and most
patients with cardiomyopathy (78%) had abnormal CXRs
consistent with the diagnosis. Therefore, while a normal
CXR is to be expected in non-physiologic causes of dyspnea,
it is also commonly seen with asthma and COPD.
Diagnostic value of PFTs
Twenty-nine patients had COPD or isolated emphysema
without airflow obstruction. Mean FEV1 was 59% of pre-
dicted (range 34e110), mean FEV1/FVC ratio was 55%
(range 36e100%), and mean DLCO was 47% of predicted
(range 30e66). Three of the 29 had emphysema with
minimal or no airflow obstruction; (FEV1s were 110%, 82%,
and 72% of predicted, FEV1/FVC ratios of 0.73, 0.64, 0.76).
For all 3, DLCO was low (39%, 41%, and 44% of predicted)
and chest CT scans showed extensive emphysema.
Forty-two/80 BPCs demonstrated bronchial hyper-
responsiveness (BHR). Twenty-nine/42 patients (69%) with
a positive BPC had asthma or asthma/COPD; BPC was false
positive in 13 (i.e. no improvement with asthma treatment,
another cause of dyspnea determined.) The mean provoc-
ative concentration causing a 20% decrease from the
baseline FEV1 (PC20) for true positives was 0.88 mg/ml
(1.13), while the mean PC20 for false positives was
2.68 mg/ml (2.31) (p Z 0.023). No patient with negative
BPC had asthma. Thirteen patients with asthma (or
asthma/COPD) did not undergo BPC due to a baseline
FEV1 < 70%. For these patients, asthma was diagnosed
based upon improvement following treatment; FEV1
increased an average of 41%, FVC an average of 42%, and
mean post-treatment FEV1 was normal at 84% of predicted
(range 71e106%).
A reduction in DLCO (<75% of predicted)17 was present
in 78/122 patients (64%). It was useful despite this high
prevalence. It was reduced in all patients with COPD (see
above) and ILD (mean 35% of predicted, range 20e64). It
was normal in all patients with non-physiologic (psycho-
genic) dyspnea.
Diagnostic value of CPET
Sixty-sevenpatients underwentCPET.Resultswerenormal in
36 and abnormal in 27. Effort was sub-optimal in 4. In 26/29
patients with a normal CPET (90%), a non-cardiorespiratory
disorder was found. There were 3 “falsely negative” studies
(2 ILD, 1 cardiomyopathy). In 25/27 patients with an
abnormal CPET (93%), the physiologic abnormality was
consistent with the final diagnosis (i.e. true positive test).
Excluding the 4 patients with sub-optimal effort and the 7 in
whom the CPETwas done for a suspected additional cause of
dyspnea (established diagnoses of asthma in 5 and anemia in
2), CPET accurately guided the work-up in 51/56 patients.
Tier III studies
There were 95 Tier III studies (81 non-invasive and 14 inva-
sive). In some cases, one Tier III study led to one or more
additional Tier III studies to more precisely define the diag-
nosis (e.g. abnormal stress test lead to cardiac catheteriza-
tion, abnormal chest CT scan led to bronchoscopy). The 81
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diograms (resting þ/ exercise), 10 nuclear stress tests, 4
ventilation/perfusion (V/Q) scans, and 1 sinus CTscan. There
were11normaland25abnormalchestCTs.All 25abnormalCT
scans were diagnostically useful (ILD, sarcoidosis, emphy-
sema with or without airflow obstruction, pneumonia, lung
cancer, and pleural disease). Of the 30 echocardiograms, 20
were abnormal and 10 normal. Eighteen/20 abnormal echoes
were true positive (showing abnormalities e left ventricular
diastolic, systolic, or valvular dysfunction or evidence of
right-sided dysfunction e eventually determined to be the
etiology of dyspnea). A normal echocardiogram ruled out
a cardiovascular cause of dyspnea 100% of the time (10/10).
Therewere 10 nuclear cardiac stress tests (3 trueþ, 1 falseþ,
6 true- for ischemic heart disease). Two/four V/Q scans were
diagnostic (1 atrial septal defect with right to left shunt, 1
pulmonary hypertension due to chronic pulmonary embo-
lism). The sinus CT showed chronic sinusitis.
The 14 invasive studies included 7 heart catheterizations,
4 bronchoscopies, one upper gastrointestinal endoscopy, 1
thoracentesis, andone skinbiopsy. All 4 bronchoscopieswere
diagnostic (3 sarcoidosis and 1 lung cancer). Six/seven heart
catheterizations were positive (aortic stenosis, cardiomy-
opathy, chronic pulmonary thromboembolism, idiopathic
pulmonaryhypertension, atrial septal defectwithpulmonary
hypertension, and mitral stenosis with pulmonary hyper-
tension). The thoracentesis demonstrated pleural effusion.
The UGI endoscopy showed Barrett’s epithelium in patient
with dyspnea due to gastroesophageal reflux disease (GERD).
In each case, dyspnea improved with treatment.
Response to therapy
Follow-up dyspnea scores were obtained in 110 patients three
months post therapy. Seventy-two were improved, 31
unchanged, and 7 worse. Thirty one of 37 patients with “pure
airway disease” (asthma or COPD with no secondary diag-
noses) had moderate or greater improvement. For asthma,
mean improvement was 3.2. In 18/23 the improvement was
moderate or better. One patient with no improvement had
occupational asthma but refused to change the work envi-
ronment.Twopatientswithairwaydiseasewere lost to follow-
up.Patientswithcardiomyopathyhadmoderate improvement
(mean 3.2). There was marked improvement in all patients
with dyspnea due to anemia, gastroesophageal reflux disease
(GERD), post-nasal drip, pregnancy, and pneumonia.
Thirteen/fourteenwith isolatedobesity showednochange.
Eight/twelve patients with ILD showed some improvement
(mean 2.6). For the 11 patients with non-physiologic (psycho-
genic) dyspnea, 4 showed marked improvement, 1 moderate
improvement, and 6 no change.
Discussion
This is the fourth prospective study of patients presenting
with chronic dyspnea and the first to establish and follow an
algorithm. Pratter et al.4 studied patients presenting with
chronic dyspnea and demonstrated that a diagnosis could
usually be established and that PFTs with BPC, imaging, and
CPET all had diagnostic value. The data of DePaso et al.2
demonstrated again the capacity to achieve a diagnosis ina majority of cases and the value of BPC. Martinez et al.3
echoed the above findings and showed that CPET was
valuable in determining the etiology of dyspnea, that
“CPET results are a useful guide to further diagnosis and
treatment”. Martinez et al. also noted that their study and
the two that preceded theirs, “suffered from a lack of
a standardized subsequent testing protocol and lack of
routine bronchoprovocation testing”. The algorithm in the
current study was based upon these earlier studies2e4 and
upon an exhaustive review of the literature on dyspnea.5
We believe that it incorporates important prior findings
into an organized approach.
The approach used in this study was useful; a diagnosis
was made in 99% of patients. Tier I findings (H&P, PFTs,
blood tests, and CXR) diagnosed 45 patients, Tier II (CPET)
diagnosed an additional 38, and focused Tier III studies an
additional 39. Thus each Tier diagnosed approximately one
third of the patients. Invasive testing was minimized; there
were only 14 invasive studies, and 13 of them diagnosed the
cause of dyspnea.
The data demonstrate that Tiers I and II together acted
as a “check and balance” system which ensured that
a significant physiologic abnormality was not missed. If Tier
I and Tier II were both normal, a non-cardiorespiratory
diagnosis was always made and Tier III studies were
uniformly negative. If Tier I or II demonstrated abnormali-
ties that were non-diagnostic, those abnormalities were
nevertheless valuable in guiding Tier III studies.
Our data generated a number of key points: One,
patients presenting with dyspnea have a wide range of
underlying diagnoses; a narrow subspecialty focus is likely
to be less successful than a broader multidisciplinary
perspective. Two, Objective data is vital; clinical suspicion
based upon H&P alone cannot replace physiologic testing.
The value of BPC was re-confirmed; BPC should be per-
formed early in any approach to dyspnea when baseline
spirometry is normal. The results of CPET establish some
diagnoses and lead to specific testing for others. Third,
response to therapy is a helpful in diagnosing conditions
where effective therapy is available. It allows the clinician
to determine whether a patient with laboratory evidence
for a diagnosis (e.g. positive BPC as evidence for asthma)
actually responds to therapy that is expected to work.
Although response to therapy does not prove the diagnosis,
it does add additional evidence.
The most important contribution of this study is the
algorithm, with specific sequenced testing for Tiers I and II.
In addition to the algorithm, our data generate new points
relevant to dyspnea: Obesity was disproportionately rep-
resented in patients with dyspnea compared to the general
population. Anemia can cause dyspnea; hemoglobin is
a valuable early test. P-BNP (not available for the prior
studies) is valuable although not diagnostic for suggesting
a cardiovascular disorder.
As with any clinical study, this one is open to criticisms.
First, both dyspnea and response to therapy are subjective,
making any objective study difficult; while we found an
explanation for dyspnea in 99% of patients, there is no
independent gold standard for comparison. There is also no
comparator or standard practice in the literature against
which we can directly compare our algorithm. Therefore,
while we believe it is a useful approach that is likely to be
1020 M.R. Pratter et al.more cost effective and efficient than the “routine”, non
algorithmic approach typically used in clinical practice, we
do not have proof that this is true. Second, the algorithmwas
not a rigid sequence, as any data suggesting a diagnosis could
lead to treatment. It was in a sense an “open algorithm”;
potentially diagnostic clinical data (such as a positive BPC)
were pursued, but if diagnosis-specific treatment was not
fruitful, the patient was returned to the algorithm and its
specified sequence. Third, CPET data are complex, and
others could disagree with their interpretation. Fourth, any
equivocal data were reviewed and agreed upon by consensus
of all the investigators, a process neither available nor
realistic in most clinical settings. Fifth, the choice of Tier III
studies was based upon study data and not upon a set
sequence, and thus required clinical judgment. It is also
possible that some Tier III tests (and even CPET) were
redundant and we could have made the diagnosis without
them.Wedo not believe this was a common occurrence since
our goalwas to stop thework-up as soon aswe felt a diagnosis
(diagnoses) was firmly established, but it certainly remains
a possibility. Alternatively, even though wemade a diagnosis
(or diagnoses) in almost every patient it is still possible that
there were additional diagnoses present that we missed in
somepatients that further testingmight have demonstrated.
We feel that despite these issues, the findings are relevant to
clinicalmedicine. Nevertheless, it should bepointed out that
our patient population had been specifically referred to us as
pulmonologists. Therefore, it is quite possible that the
frequency and distribution of diagnoses associated with
dyspnea would prove to be different in an internal medicine
or cardiology subspecialty practice. In addition, the relative
value and optimal sequence of diagnostic tests might prove
to be significantly different from our algorithm. We believe,
however, that a systematic, organized approach analogous
to what we used in this study would likely prove to be
beneficial in these settings.
Based on our results we would revise the algorithm,
specifically Tier I. We would recommend physician judgment
in deciding whether to obtain blood studies if the PFTs or
CXR strongly support a specific diagnosis. While we would
suggest, based on the low diagnostic yield in this study, that
a TSH or blood chemistries do not need to be automatically
obtained, they are low cost and occasionally may be helpful
(e.g. a high TSH suggesting hypothyroidism or a high CO2
suggesting obesity hypoventilation). If baseline spirometry is
normal we would not routinely obtain full lung volumes. We
would only obtain a P-BNP if there was at least some clinical
suspicion for cardiovascular dysfunction. Furthermore, Tier I
studies could be done sequentially during one or more visits
rather than all at once. PFTs could be obtained and if
normal or non-diagnostic a Chest X-ray could then be
obtained. If the Chest X-ray is normal or non-diagnostic
a CBC and P-BNP could be obtained to evaluate for heart
failure and anemia, respectively.
In conclusion, the findings of this study strengthen and
extend those of prior studies. The algorithm used in this
prospective study of chronic dyspnea helped organize the
approach and generally enabled the identification of
a cause or causes of dyspnea. It led to specific diagnoses,
specific treatment, and good clinical outcomes in most
patients while minimizing invasive studies. Nevertheless,
our approach can be streamlined further as noted above.The most important finding is that the physician by
following a systematic (algorithmic) approach has a high
likelihood of being successful in diagnosing the cause of
chronic dyspnea and, in the majority of patients, achieving
improvement in dyspnea and exercise tolerance through
specific treatment.Acknowledgements
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